<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02690649</url>
  </required_header>
  <id_info>
    <org_study_id>PRC15-0709</org_study_id>
    <nct_id>NCT02690649</nct_id>
  </id_info>
  <brief_title>Keep it SIMPLE: Improving Anti-Coagulation Medication Adherence</brief_title>
  <official_title>Keep it SIMPLE: Improving Anti-Coagulation Medication Adherence for Patients With Non-valvular Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tammy Toscos</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen Scientific Affairs, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Parkview Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an interventional study designed to develop patient focused strategies that improve&#xD;
      adherence to anticoagulant medication in patients with non-valvular atrial fibrillation (AF).&#xD;
      Outcomes of this work include a novel intervention, as well as information regarding patient&#xD;
      preferences for tailored education.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an interventional study designed to develop patient focused strategies that improve&#xD;
      adherence to anticoagulant medication in patients with non-valvular atrial fibrillation (AF).&#xD;
      Outcomes of this work include a novel intervention, as well as information regarding patient&#xD;
      preferences for tailored education.&#xD;
&#xD;
      There will be two phases in this study. In the first phase, the investigators will use a&#xD;
      patient-centered approach to design and build a personal health record (PHR)-based&#xD;
      educational intervention based on patient preferences for content, timing and delivery&#xD;
      mechanism. In the second phase, the investigators will test the intervention in a six-month&#xD;
      randomized controlled trial.&#xD;
&#xD;
      During the development of the intervention in Phase 1 the investigators will use a&#xD;
      patient-centered, iterative design process that includes interviews, prototype development&#xD;
      and testing. The investigators will recruit a diverse group of AF patients to determine&#xD;
      preferences for information about AF and anticoagulant therapy. The investigators will use a&#xD;
      user-centered design approach and best practices in human-computer interactions (HCI) to&#xD;
      determine the desired content, timing, and delivery of tailored education in the PHR. The&#xD;
      investigators will build out wire-frame models (low fidelity messaging prototypes) based on&#xD;
      focus group findings to perform usability testing and further refine the intervention design.&#xD;
      The intervention component will assess the impact of pushing tailored health education&#xD;
      messages to patients through their PHR. The tailored health education will be specifically&#xD;
      aimed at improving patient compliance with anticoagulant therapy.&#xD;
&#xD;
      One trigger for health education messaging will be failure to take, fill, or refill&#xD;
      anticoagulant medication prescription - information obtained from an e-prescribing data feed&#xD;
      to the electronic medical record (Surescripts) and use of a smart pill bottle (AdhereTech -&#xD;
      HIPAA compliant, FDA-registered Class I medical device) that sends notification in real time&#xD;
      when participants open or fail to open their pill bottle.&#xD;
&#xD;
      The intervention trial in Phase 2 will be comprised of two groups, control and experimental.&#xD;
      Both the control and experimental group will receive standard care, which includes access to&#xD;
      MyChart. In addition to standard care, both groups will receive training on the use of&#xD;
      MyChart and the AdhereTech smart pill bottle, and medication adherence for both groups will&#xD;
      be monitored with Surescripts e-prescribing software and AdhereTech smart pill bottle use.&#xD;
      The experimental group will receive the intervention: tailored health messaging delivered via&#xD;
      MyChart pertinent to AF and oral anticoagulant use.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Actual">October 2018</completion_date>
  <primary_completion_date type="Actual">October 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Medication Adherence</measure>
    <time_frame>6 months during study</time_frame>
    <description>AdhereTech smart pill bottles used to collect medication dosing = percentage of allotted doses that were recorded as taken</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient Portal Login</measure>
    <time_frame>6 months during study</time_frame>
    <description>The number of times participants logged into their patient portal (Epic's MyChart) during the study period was used as a proxy for patient engagement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Atrial Fibrillation Knowledge</measure>
    <time_frame>6 months</time_frame>
    <description>End of study score on Atrial Fibrillation Knowledge scale (min:0 is no knowledge, max: 11 is high knowledge), adjusted for age, baseline knowledge, gender and education level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Incidence of Adverse Events</measure>
    <time_frame>6 months during study</time_frame>
    <description>Adverse events include death, stroke, any embolic event, and/or major bleeding.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">160</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Medication Adherence</condition>
  <arm_group>
    <arm_group_label>Health Messaging (Non-Procedural)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PHR messaging of tailored health education pertinent to non-valvular atrial fibrillation and anticoagulant use.&#xD;
Training on the use of MyChart and the AdhereTech smart pill bottle, medication adherence monitored with Surescripts e-prescribing software and AdhereTech smart pill bottle use.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No Health Messaging</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No PHR messaging of tailored health education pertinent to non-valvular atrial fibrillation and anticoagulant use.&#xD;
Standard care, training on the use of MyChart and the AdhereTech smart pill bottle, medication adherence monitored with Surescripts e-prescribing software and AdhereTech smart pill bottle use</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Health Messaging (Non-Procedural)</intervention_name>
    <description>Tailored health messaging delivered via the PHR MyChart pertinent to non-valvular atrial fibrillation and anticoagulant use. Messages will be triggered by medication non-adherence information obtained from Surescripts e-prescribing data and use of AdhereTech smart pill bottle.</description>
    <arm_group_label>Health Messaging (Non-Procedural)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        FOCUS GROUPS:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of Atrial Fibrillation (Paroxysmal, Persistent, Permanent)&#xD;
&#xD;
               -  focus groups 1 &amp; 2: patients diagnosed ≤ 6 months&#xD;
&#xD;
               -  focus groups 3 &amp; 4: patients diagnosed ≥ 6 months&#xD;
&#xD;
          2. Receiving Oral Anticoagulation -Vitamin K Antagonist (VKA) or Novel Oral Anticoagulant&#xD;
             (NOAC)- for non-valvular AF&#xD;
&#xD;
               -  focus groups 1 &amp; 2: on VKA or NOAC&#xD;
&#xD;
               -  focus groups 3 &amp; 4: changed VKA to NOAC within last 6 months&#xD;
&#xD;
          3. *Physically and Mentally capable of providing Informed Consent&#xD;
&#xD;
          4. *Age 18 years or older&#xD;
&#xD;
          5. *Ability to read and understand English&#xD;
&#xD;
          6. Current Patient of Parkview Physicians Group (PPG)-Cardiology&#xD;
&#xD;
               -  3, 4, and 5 must apply to caregivers, partners, and/or support persons&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Absence of History of Atrial Fibrillation (AF)&#xD;
&#xD;
          2. *Does not meet Inclusion Criteria&#xD;
&#xD;
          3. Anticoagulation with VKA or NOAC for reasons other than non-valvular AF&#xD;
&#xD;
          4. *Designated as part of a vulnerable subject population that the investigator or&#xD;
             designee identifies to have compromised autonomy related to potential study&#xD;
             participation&#xD;
&#xD;
          5. Currently participating in another Parkview study that involves PHR use&#xD;
&#xD;
               -  Only 2 and 4 apply to caregivers, partners, and/or support persons&#xD;
&#xD;
        TECHNOLOGY TRIAL:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of Atrial Fibrillation (Paroxysmal, Persistent, Permanent)&#xD;
&#xD;
          2. Receiving Oral Anticoagulation (VKA or NOAC) for non-valvular AF&#xD;
&#xD;
          3. Physically and Mentally capable of providing Informed Consent&#xD;
&#xD;
          4. Age 18 years or older&#xD;
&#xD;
          5. Access to Computer and Internet&#xD;
&#xD;
          6. Ability to read and understand English&#xD;
&#xD;
          7. Current Patient of PPG-Cardiology&#xD;
&#xD;
          8. Willing to have a MyChart account&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Absence of History of Atrial Fibrillation (AF)&#xD;
&#xD;
          2. Does not meet Inclusion Criteria&#xD;
&#xD;
          3. Anticoagulation with VKA or NOAC for reasons other than non-valvular AF&#xD;
&#xD;
          4. Unable to physically or cognitively carry out the tasks necessary for utilizing a PHR&#xD;
             such as; blindness, loss of function of arms, cognitive impairments (per chart review)&#xD;
             that would interfere in learning a new task&#xD;
&#xD;
          5. Designated as part of a vulnerable subject population that the investigator or&#xD;
             designee identifies to have compromised autonomy related to potential study&#xD;
             participation&#xD;
&#xD;
          6. Currently participating in another Parkview study that involves PHR use&#xD;
&#xD;
          7. Not willing to have a MyChart account&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tammy Toscos, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Parkview Research Center; Parkview Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Mirro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Parkview Research Center; Parkview Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Parkview Research Center; Parkview Health</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46845</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 10, 2016</study_first_submitted>
  <study_first_submitted_qc>February 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2016</study_first_posted>
  <results_first_submitted>October 27, 2019</results_first_submitted>
  <results_first_submitted_qc>October 26, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">October 28, 2021</results_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Parkview Health</investigator_affiliation>
    <investigator_full_name>Tammy Toscos</investigator_full_name>
    <investigator_title>Research Scientist, Informatics</investigator_title>
  </responsible_party>
  <keyword>anticoagulants</keyword>
  <keyword>Personal Health Records</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is no plan to make individual participant data available.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 30, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/49/NCT02690649/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Health Messaging (Non-Procedural)</title>
          <description>PHR messaging of tailored health education pertinent to non-valvular atrial fibrillation and anticoagulant use.&#xD;
Health Messaging (Non-Procedural): Tailored health messaging delivered via the PHR MyChart pertinent to non-valvular atrial fibrillation and anticoagulant use. Messages will be triggered by medication non-adherence information obtained from Surescripts e-prescribing data and use of AdhereTech smart pill bottle.</description>
        </group>
        <group group_id="P2">
          <title>No Health Messaging</title>
          <description>No PHR messaging of tailored health education pertinent to non-valvular atrial fibrillation and anticoagulant use.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="80"/>
                <participants group_id="P2" count="80"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="79"/>
                <participants group_id="P2" count="76"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Health Messaging (Non-Procedural)</title>
          <description>PHR messaging of tailored health education pertinent to non-valvular atrial fibrillation and anticoagulant use.&#xD;
Health Messaging (Non-Procedural): Tailored health messaging delivered via the PHR MyChart pertinent to non-valvular atrial fibrillation and anticoagulant use. Messages will be triggered by medication non-adherence information obtained from Surescripts e-prescribing data and use of AdhereTech smart pill bottle.</description>
        </group>
        <group group_id="B2">
          <title>No Health Messaging</title>
          <description>No PHR messaging of tailored health education pertinent to non-valvular atrial fibrillation and anticoagulant use.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="80"/>
            <count group_id="B2" value="80"/>
            <count group_id="B3" value="160"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="80"/>
                    <count group_id="B2" value="80"/>
                    <count group_id="B3" value="160"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70.78" spread="8.65"/>
                    <measurement group_id="B2" value="71.51" spread="8.21"/>
                    <measurement group_id="B3" value="71.14" spread="8.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="80"/>
                    <count group_id="B2" value="80"/>
                    <count group_id="B3" value="160"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Atrial Fibrillation Knowledge</title>
          <description>0 is no knowledge, 11 is high knowledge</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="80"/>
                    <count group_id="B2" value="80"/>
                    <count group_id="B3" value="160"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.94" spread="1.93"/>
                    <measurement group_id="B2" value="6.59" spread="2.13"/>
                    <measurement group_id="B3" value="6.76" spread="2.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pre-intervention Patient Portal Logins</title>
          <units>logins</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="80"/>
                    <count group_id="B2" value="80"/>
                    <count group_id="B3" value="160"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17.80" spread="18.83"/>
                    <measurement group_id="B2" value="18.60" spread="20.85"/>
                    <measurement group_id="B3" value="18.20" spread="19.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Medication Type</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="80"/>
                    <count group_id="B2" value="80"/>
                    <count group_id="B3" value="160"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Warfarin</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="80"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Xarelto</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Eliquis</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Atrial fibrillation diagnosis in previous 12 months</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="80"/>
                    <count group_id="B2" value="80"/>
                    <count group_id="B3" value="160"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="73"/>
                    <measurement group_id="B3" value="136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Medication Adherence</title>
        <description>AdhereTech smart pill bottles used to collect medication dosing = percentage of allotted doses that were recorded as taken</description>
        <time_frame>6 months during study</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Health Messaging (Non-Procedural)</title>
            <description>PHR messaging of tailored health education pertinent to non-valvular atrial fibrillation and anticoagulant use.&#xD;
Health Messaging (Non-Procedural): Tailored health messaging delivered via the PHR MyChart pertinent to non-valvular atrial fibrillation and anticoagulant use. Messages will be triggered by medication non-adherence information obtained from Surescripts e-prescribing data and use of AdhereTech smart pill bottle.</description>
          </group>
          <group group_id="O2">
            <title>No Health Messaging</title>
            <description>No PHR messaging of tailored health education pertinent to non-valvular atrial fibrillation and anticoagulant use.</description>
          </group>
        </group_list>
        <measure>
          <title>Medication Adherence</title>
          <description>AdhereTech smart pill bottles used to collect medication dosing = percentage of allotted doses that were recorded as taken</description>
          <units>percentage of doses recorded as taken</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.08" spread="0.01"/>
                    <measurement group_id="O2" value="89.52" spread="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>estimated adherence rate for the intervention group Generalized linear models were used to test the effect of the intervention on medication adherence. These generalized linear models used a Poisson distribution to estimate the rate of adherence with the log of total prescribed doses as an offset term in the linear predictor.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.28</p_value>
            <method>Regression, Linear</method>
            <param_type>estimated adherence rate for the interve</param_type>
            <param_value>94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>92</ci_lower_limit>
            <ci_upper_limit>95</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Portal Login</title>
        <description>The number of times participants logged into their patient portal (Epic's MyChart) during the study period was used as a proxy for patient engagement.</description>
        <time_frame>6 months during study</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Health Messaging (Non-Procedural)</title>
            <description>PHR messaging of tailored health education pertinent to non-valvular atrial fibrillation and anticoagulant use.&#xD;
Health Messaging (Non-Procedural): Tailored health messaging delivered via the PHR MyChart pertinent to non-valvular atrial fibrillation and anticoagulant use. Messages will be triggered by medication non-adherence information obtained from Surescripts e-prescribing data and use of AdhereTech smart pill bottle.</description>
          </group>
          <group group_id="O2">
            <title>No Health Messaging</title>
            <description>No PHR messaging of tailored health education pertinent to non-valvular atrial fibrillation and anticoagulant use.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Portal Login</title>
          <description>The number of times participants logged into their patient portal (Epic's MyChart) during the study period was used as a proxy for patient engagement.</description>
          <units>Count of MyChart patient portal logins</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.7" spread="37.0"/>
                    <measurement group_id="O2" value="15.9" spread="16.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>A negative binomial distribution because the outcome was a count variable and it was over-dispersed.</p_value_desc>
            <method>Regression, Linear</method>
            <method_desc>Age, previous patient portal logins, and gender were used as co-variates in the model.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Atrial Fibrillation Knowledge</title>
        <description>End of study score on Atrial Fibrillation Knowledge scale (min:0 is no knowledge, max: 11 is high knowledge), adjusted for age, baseline knowledge, gender and education level.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Health Messaging (Non-Procedural)</title>
            <description>PHR messaging of tailored health education pertinent to non-valvular atrial fibrillation and anticoagulant use.&#xD;
Training on the use of MyChart and the AdhereTech smart pill bottle, medication adherence monitored with Surescripts e-prescribing software and AdhereTech smart pill bottle use.&#xD;
Health Messaging (Non-Procedural): Tailored health messaging delivered via the PHR MyChart pertinent to non-valvular atrial fibrillation and anticoagulant use. Messages will be triggered by medication non-adherence information obtained from Surescripts e-prescribing data and use of AdhereTech smart pill bottle.</description>
          </group>
          <group group_id="O2">
            <title>No Health Messaging</title>
            <description>No PHR messaging of tailored health education pertinent to non-valvular atrial fibrillation and anticoagulant use.&#xD;
Standard care, training on the use of MyChart and the AdhereTech smart pill bottle, medication adherence monitored with Surescripts e-prescribing software and AdhereTech smart pill bottle use</description>
          </group>
        </group_list>
        <measure>
          <title>Atrial Fibrillation Knowledge</title>
          <description>End of study score on Atrial Fibrillation Knowledge scale (min:0 is no knowledge, max: 11 is high knowledge), adjusted for age, baseline knowledge, gender and education level.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.31" spread="1.92"/>
                    <measurement group_id="O2" value="6.64" spread="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.03</p_value>
            <p_value_desc>baseline AF knowledge, gender, age, and educational level were all used as co-variates.</p_value_desc>
            <method>Regression, Linear</method>
            <method_desc>generalized linear model tested whether AF knowledge at study completion was related to baseline AF knowledge, gender, age, and educational level</method_desc>
            <param_type>Slope</param_type>
            <param_value>-0.61</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.14</ci_lower_limit>
            <ci_upper_limit>-0.07</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Incidence of Adverse Events</title>
        <description>Adverse events include death, stroke, any embolic event, and/or major bleeding.</description>
        <time_frame>6 months during study</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Health Messaging (Non-Procedural)</title>
            <description>PHR messaging of tailored health education pertinent to non-valvular atrial fibrillation and anticoagulant use.&#xD;
Health Messaging (Non-Procedural): Tailored health messaging delivered via the PHR MyChart pertinent to non-valvular atrial fibrillation and anticoagulant use. Messages will be triggered by medication non-adherence information obtained from Surescripts e-prescribing data and use of AdhereTech smart pill bottle.</description>
          </group>
          <group group_id="O2">
            <title>No Health Messaging</title>
            <description>No PHR messaging of tailored health education pertinent to non-valvular atrial fibrillation and anticoagulant use.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Incidence of Adverse Events</title>
          <description>Adverse events include death, stroke, any embolic event, and/or major bleeding.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months time of study</time_frame>
      <desc>The intervention was education only; not clinical.</desc>
      <group_list>
        <group group_id="E1">
          <title>Health Messaging (Non-Procedural)</title>
          <description>PHR messaging of tailored health education pertinent to non-valvular atrial fibrillation and anticoagulant use.&#xD;
Health Messaging (Non-Procedural): Tailored health messaging delivered via the PHR MyChart pertinent to non-valvular atrial fibrillation and anticoagulant use. Messages will be triggered by medication non-adherence information obtained from Surescripts e-prescribing data and use of AdhereTech smart pill bottle.</description>
        </group>
        <group group_id="E2">
          <title>No Health Messaging</title>
          <description>No PHR messaging of tailored health education pertinent to non-valvular atrial fibrillation and anticoagulant use.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <description>Chest Pain Hospitalization</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GI Bleed</sub_title>
                <description>GI Bleed Hospitalization</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza A</sub_title>
                <description>Influenza A Hospitalization</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <description>UTI Hospitalization</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular Parkinsonism with dementia</sub_title>
                <description>Vascular Parkinsonism with dementia Hospitalization</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Worsening Dyspnea</sub_title>
                <description>Worsening Dyspnea Emergency Room Visit</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <description>Palpitations Emergency Room Visit</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <description>Chest Pain Emergency Room Visit</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <description>Atrial Fibrillation Emergency Room Visit</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vestibular Schwannoma</sub_title>
                <description>Vestibular Schwannoma Emergency Room Visit</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes Type 2</sub_title>
                <description>Emergency Room Visit</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <description>Abdominal pain Emergency Room Visit</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Penile and Scrotal Rash</sub_title>
                <description>Penile and Scrotal Rash Emergency Room Visit</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Hematuria</sub_title>
                <description>Hematuria Emergency Room Visit</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <description>Gout Emergency Room Visit</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Ankle pain, arthritis</sub_title>
                <description>Ankle pain, arthritis Emergency Room Visit</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Julie Hughbanks</name_or_title>
      <organization>Parkview Health</organization>
      <phone>260-266-1444</phone>
      <email>julie.hughbanks@parkview.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

